Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Recruiting 6Unknown 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 175Thoracic 36Gastrointestinal 33Gynecologic 24Breast 22Head & Neck 20Dermatologic 20Sarcoma 12Other solid neoplasm 5Lymphoid 5CNS 5Plasma cell 2Other hematologic neoplasm 2Myeloid 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 46Pituitary Neoplasms 19Neoplasms 14Thyroid Neoplasms 13Pheochromocytoma 13Thyroid Carcinoma, Anaplastic 12Thyroid Cancer, Papillary 12Neoplasm Metastasis 12Adrenocortical Carcinoma 11Paraganglioma 9Insulinoma 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Somatostatinoma 8Glucagonoma 8Colorectal Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Islet Cell 8Pancreatic Neoplasms 7Gastrinoma 7Carcinoma, Neuroendocrine 7Breast Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Adenoma, Islet Cell 6Small Cell Lung Carcinoma 5Multiple Endocrine Neoplasia Type 1 5Lung Neoplasms 5Gastro-enteropancreatic neuroendocrine tumor 5

Interventions

tovorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Endocrine × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡